JP2018516244A5 - - Google Patents

Download PDF

Info

Publication number
JP2018516244A5
JP2018516244A5 JP2017554475A JP2017554475A JP2018516244A5 JP 2018516244 A5 JP2018516244 A5 JP 2018516244A5 JP 2017554475 A JP2017554475 A JP 2017554475A JP 2017554475 A JP2017554475 A JP 2017554475A JP 2018516244 A5 JP2018516244 A5 JP 2018516244A5
Authority
JP
Japan
Prior art keywords
seq
antibody
fra
composition
use according
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2017554475A
Other languages
English (en)
Japanese (ja)
Other versions
JP2018516244A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2016/027497 external-priority patent/WO2016168440A1/en
Publication of JP2018516244A publication Critical patent/JP2018516244A/ja
Publication of JP2018516244A5 publication Critical patent/JP2018516244A5/ja
Pending legal-status Critical Current

Links

JP2017554475A 2015-04-17 2016-04-14 肺がんを処置するための方法 Pending JP2018516244A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201562149184P 2015-04-17 2015-04-17
US62/149,184 2015-04-17
PCT/US2016/027497 WO2016168440A1 (en) 2015-04-17 2016-04-14 Methods for treating lung cancer

Publications (2)

Publication Number Publication Date
JP2018516244A JP2018516244A (ja) 2018-06-21
JP2018516244A5 true JP2018516244A5 (cg-RX-API-DMAC7.html) 2019-03-28

Family

ID=55809240

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2017554475A Pending JP2018516244A (ja) 2015-04-17 2016-04-14 肺がんを処置するための方法

Country Status (13)

Country Link
US (1) US20180125970A1 (cg-RX-API-DMAC7.html)
EP (1) EP3283886B1 (cg-RX-API-DMAC7.html)
JP (1) JP2018516244A (cg-RX-API-DMAC7.html)
KR (1) KR20170137848A (cg-RX-API-DMAC7.html)
CN (1) CN107624071A (cg-RX-API-DMAC7.html)
AU (1) AU2016248222A1 (cg-RX-API-DMAC7.html)
BR (1) BR112017022320A2 (cg-RX-API-DMAC7.html)
CA (1) CA2983126A1 (cg-RX-API-DMAC7.html)
IL (1) IL255079A0 (cg-RX-API-DMAC7.html)
MX (1) MX2017013390A (cg-RX-API-DMAC7.html)
RU (1) RU2718780C9 (cg-RX-API-DMAC7.html)
SG (1) SG11201708546UA (cg-RX-API-DMAC7.html)
WO (1) WO2016168440A1 (cg-RX-API-DMAC7.html)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2009521206A (ja) * 2005-04-22 2009-06-04 モルフォテック、インク. 免疫エフェクター活性を有する葉酸受容体アルファ陽性細胞に内部移行する抗体
TW201625301A (zh) * 2014-06-06 2016-07-16 Kyowa Hakko Kirin Co Ltd 藉由folr1標靶藥及葉酸代謝拮抗劑用於癌症患者之治療方法與醫藥
JP7072571B2 (ja) 2016-11-23 2022-05-20 エーザイ・アール・アンド・ディー・マネジメント株式会社 抗葉酸受容体アルファ抗体およびその使用
MX2020009522A (es) 2018-03-13 2020-10-22 Phanes Therapeutics Inc Anticuerpos anti-folato del receptor 1 y usos de los mismos.
CA3103369A1 (en) * 2018-06-18 2019-12-26 Medimmune Limited Combination of lif inhibitors and platinum-based antineoplastic agents for use in treating cancer
CN110221052B (zh) * 2019-06-17 2022-09-23 昆山德诺瑞尔生物科技有限公司 Ppfibp1蛋白在制备肝癌术后预后评估试剂盒中的应用
US20250177550A1 (en) * 2022-03-11 2025-06-05 Astrazeneca Ab A scoring method for an anti-fr alpha antibody drug conjugate therapy

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050232919A1 (en) * 2004-02-12 2005-10-20 Morphotek, Inc. Monoclonal antibodies that specifically block biological activity of a tumor antigen
JP2009521206A (ja) * 2005-04-22 2009-06-04 モルフォテック、インク. 免疫エフェクター活性を有する葉酸受容体アルファ陽性細胞に内部移行する抗体
GB0718167D0 (en) * 2007-09-18 2007-10-31 Cancer Rec Tech Ltd Cancer marker and therapeutic target
RU2630608C2 (ru) 2010-11-05 2017-09-11 Морфотек Инк. Рецептор фолиевой кислоты альфа в качестве диагностического и прогностического маркера злокачественных опухолей, экспрессирующих рецептор фолиевой кислоты альфа
PL2731972T3 (pl) 2011-07-15 2018-06-29 Eisai R&D Management Co., Ltd. Przeciwciała skierowane przeciwko receptorowi folianowemu alfa i ich zastosowania

Similar Documents

Publication Publication Date Title
JP2018516244A5 (cg-RX-API-DMAC7.html)
JP7325463B2 (ja) がんの予後診断及び治療のための方法及び組成物
US20250154257A1 (en) Treatment of lung cancer using a combination of an anti-pd-1 antibody and an anti-ctla-4 antibody
AU2014312079B2 (en) Diagnostic methods and compositions for treatment of glioblastoma
US20220315657A1 (en) Anti-pd-1 antibody for use in a method of treating a tumor
RU2017136863A (ru) Способы лечения рака легкого
JP2020524694A (ja) がんの処置における使用のためのIL−1β結合性抗体
JP2016539083A5 (cg-RX-API-DMAC7.html)
KR20130055647A (ko) 항암요법에 반응할 가능성이 증가된 환자를 확인하는 방법
TWI819011B (zh) 以pd-1 軸結合拮抗劑、鉑劑及拓撲異構酶ii 抑制劑治療肺癌之方法
WO2016011052A1 (en) Diagnostic methods and compositions for treatment of glioblastoma
US12183434B2 (en) Diagnostic and therapeutic methods for cancer
US20200369762A1 (en) Use of il-1beta binding antibodies
WO2014205342A4 (en) Methods for treatment of ovarian cancer
JP2016529484A5 (cg-RX-API-DMAC7.html)
JP6312660B2 (ja) Tk1タンパク質の発現が亢進した結腸直腸癌患者に対する治療効果予測方法
WO2025080769A1 (en) Methods of treating cancer
JPWO2022043538A5 (cg-RX-API-DMAC7.html)
HK1230250A1 (en) Diagnostic methods and compositions for treatment of glioblastoma
HK1244302A1 (en) Methods and compositions for prognosis and treatment of cancers